Cipla CIPLA
No. 3 Indian branded formulations company and respiratory specialist, with a US complex-generics (inhalers, peptides) business and South Africa
Mapped in 2 themes: Nifty 50 and Pharmaceuticals.
Where Cipla sits in the supply chain
Cipla appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Index membership
Cipla is in the Nifty 50 (NSE industry: Healthcare).
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 25,774 | 27,548 | 28,163 |
| Net profit | 4,154 | 5,269 | 3,862 |
Latest-year revenue ₹28,163 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- India's respiratory/inhalation leader - India is the largest and fastest-growing segment ('One India' had a record Q1 FY27)
- US inhaler capability: gAdvair Diskus approved Jul 2026 from its New York plant (US onshore - a tariff hedge), gAlbuterol, gVentolin
- Net-cash balance sheet
Risks
- gRevlimid has ended and lanreotide supply was disrupted - Q1 FY27 profit fell 39% YoY
- North America revenue (~US$160m a quarter) depends on a few complex launches arriving on time
- USFDA compliance history at Goa and other sites
Common questions
What does Cipla do?
No. 3 Indian branded formulations company and respiratory specialist, with a US complex-generics (inhalers, peptides) business and South Africa.
Where does Cipla sit in the supply chain?
Cipla (NSE: CIPLA) is mapped in 2 supply-chain layers: India branded formulations (Pharmaceuticals) and Generics (US & export) (Pharmaceuticals).
Who are Cipla's peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Sun Pharmaceutical Industries, Alembic Pharmaceuticals and 6 more.
What is Cipla's market cap and valuation?
As of 30 Oct 2026: market cap ₹1.11L Cr, P/E 35.9x, ROCE 15.5%, ROE 11.6%, dividend yield 0.94%.